SPOTLIGHT: Coated stents better for at-risk patients

Another day, another stent study. Research published in the New England Journal of Medicine shows that drug-coated stents actually worked better than bare-metal models in a specific subset of high-risk patients. The drug-eluting sort were less likely to spawn new procedures and didn't significantly boost heart attacks--but only in patients at risk of a condition called restenosis. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?